The lack of awareness of heart valve
disease amongst both patients and healthcare professionals is of increasing concern due to the poor prognosis if left untreated.
TAVI is likely to become an important treatment option in the US for heart valve
replacement due to its minimally invasive nature, clinical efficacy, extensive patient experience as an approved procedure in Europe, and reduced procedural costs.
Using a patient's own heart muscle cells as seeds for new tissue, researchers are testing a novel technique to "grow" replacement heart valves
for persons with cardiac disease.
8 Transcatheter Heart Valve
Market, Mexico, Revenue and Volume, 2007 - 2020
Children's and Tepha say previous attempts to engineer new tissue heart valves
have been hindered by the lack of suitable bioabsorbable materials that can endure the repetitive bi-directional flexing of the heart valve
The tissue valve segment is the largest within the prosthetic heart valve
List of Exhibits Exhibit 1: Market Research Methodology Exhibit 2: Global Heart Valve
Repair and Replacement Market 2013-2018 (US$ million) Exhibit 3: Global Heart Repair and Replacement Market by Application Exhibit 4: Global Heart Repair and Replacement Market by Application Exhibit 5: Global Heart Valve
Replacement Market 2013-2018 (US$ million) Exhibit 6: Global Heart Valve
Repair Market 2013-2018 (US$ million) Exhibit 7: Global Heart Valve
Repair and Replacement Market by Geographical Segmentation 2013 Exhibit 8: Competitive Analysis of the Global Heart Valve
Repair Market Exhibit 9: Competitive Analysis of the Global Heart Valve
In June 2015, the FDA approved Edwards Lifesciences' SAPIEN 3 Transcatheter Heart Valve
(THV) and Medtronic's CoreValve Evolut R System for treating patients who are at high risk for open-heart surgery.
approximately 70,000 heart valve
procedures are performed for mitral valve stenosis annually.
Professor Ben Bridgewater, Heart Valve
Voice Chairman and Consultant Cardiac Surgeon at University Hospital of South Manchester, said: "It is unacceptable that when effective treatments for heart valve
disease are available all patients in the UK do not receive timely diagnosis, effective referral and equal access to treatment.
It's the first fabrication of an autologous heart valve
inside a living body," Kyoko Hayashida, MD, lead author of the study, told participants attending the American Heart Association's 2006 Scientific Sessions.
The Toronto Root(TM) bioprosthesis, featuring our BiLinx(TM) anticalcification technology, continues our commitment to provide the best solutions for heart valve
disease with the broadest line of heart valve
replacement and repair products available from any supplier.